Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 6/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 6/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 6/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 5/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 5/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15184833 | 0.73 | ELANE (0.43) | CYP3A4ADRA2AADRA1AACHE | |
| SCHEMBL1925341 | 0.70 | CYP3A4 (0.41) | CYP3A4IDO1ADRA2AADRA2BADRA2C | |
| SCHEMBL7744420 | 0.69 | ACHE (0.36) | ADRA2AADRA1AACHEF2 | |
| SCHEMBL4506826 | 0.66 | MAPK10 (0.54) | CYP3A4IDO1ADRA2AADRA2BADRA2C | |
| SCHEMBL4509516 | 0.66 | RAD52 (0.48) | CYP3A4IDO1ADRA2AADRA2BADRA2C | |
| SCHEMBL4512339 | 0.66 | KDM4E (0.42) | CYP3A4IDO1ADRA2AADRA2BADRA2C | |
| SCHEMBL4504196 | 0.66 | CDK4 (0.41) | CYP3A4IDO1ADRA2AADRA2BADRA2C | |
| SCHEMBL22092723 | 0.66 | CYP11B1 (0.53) | CYP3A4IDO1 | |
| SCHEMBL31186471 | 0.66 | CYP11B1 (0.53) | CYP3A4IDO1 | |
| SCHEMBL4505370 | 0.65 | HPGD (0.45) | CYP3A4IDO1ACHEF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2104675-A1 | SUBSTITUTED 5H-PYRIMIDOL[5,4-B]INDOLES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF FOR TREATING NON-SOLID MALIGNANT TUMORS OF THE BLOOD-PRODUCING SYSTEM | The Medicines Company (Leipzig) GmbH (DE) | 2009-09-30 | — | — | EP | claimed |
| WO-2008077631-A1 | SUBSTITUTED 5H-PYRIMIDOL[5,4-B]INDOLES, METHOD FOR THE PRODUCTION THEREOF, AND USE THEREOF FOR TREATING NON-SOLID MALIGNANT TUMORS OF THE BLOOD-PRODUCING SYSTEM | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2008-07-03 | — | — | WO | claimed |
| EP-0552237-A1 | CERTAIN CYCLOALKYL AND AZACYCLOALKYL PYRROLOPYRIMIDINES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1993-07-28 | — | — | EP | claimed |
| WO-1992006094-A1 | CERTAIN CYCLOALKYL AND AZACYCLOALKYL PYRROLOPYRIMIDINES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1992-04-16 | — | — | WO | claimed |
| US-20260000777-A1 | NECTIN-4 ANTIBODY CONJUGATES AND USES THEREOF | ARARIS BIOTECH AG (CH) | 2026-01-01 | — | — | US | disclosed |
| US-12364768-B2 | Nectin-4 antibody conjugates and uses thereof | ARARIS BIOTECH AG (CH) | 2025-07-22 | — | — | US | disclosed |
| US-20230218733-A1 | RAPID VACCINE PLATFORM | CYTONUS THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| EP-4175673-A1 | ANTI-ASGR1 ANTIBODY CONJUGATES AND USES THEREOF | ARS Pharmaceuticals Inc. (US) | 2023-05-10 | — | — | EP | disclosed |
| US-20230093147-A1 | METHODS AND COMPOSITIONS RELATING TO IMPROVED COMBINATION THERAPIES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-03-23 | — | — | US | disclosed |
| US-20230062712-A1 | ANTI-ASGR1 ANTIBODY CONJUGATES AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-11541126-B1 | Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereof | SILVERBACK THERAPEUTICS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| EP-4106819-A1 | NECTIN-4 ANTIBODY CONJUGATES AND USES THEREOF | Silverback Therapeutics, Inc. (US) | 2022-12-28 | — | — | EP | disclosed |
| US-7326712-B2 | Substituted tricyclic compounds as protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2008-02-05 | — | — | US | disclosed |
| US-7312226-B2 | Substituted tricyclic compounds as protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2007-12-25 | — | — | US | disclosed |
| US-7109351-B1 | Fused pyrrolecarboxamides; GABA brain receptor ligands | NEUROGEN CORPORATION (US) | 2006-09-19 | — | — | US | disclosed |
| US-20050277658-A1 | Protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2005-12-15 | — | — | US | disclosed |
| US-20050239793-A1 | Protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2005-10-27 | — | — | US | disclosed |
| US-20050239794-A1 | Protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2005-10-27 | — | — | US | disclosed |
| US-20050227992-A1 | Protein kinase inhibitors | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2005-10-13 | — | — | US | disclosed |
| US-20050014939-A1 | Fused pyrrolecarboxamides: GABA brain receptor ligands | NEUROGEN CORPORATION | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000777-A1 | NECTIN-4 ANTIBODY CONJUGATES AND USES THEREOF | NECTIN4, IGSF11, VSIG8 | CYP3A4 1555/4885IDO1 265/4885ADRA2A 2266/4885 |
| US-20050014939-A1 | Fused pyrrolecarboxamides: GABA brain receptor ligands | GABRB2, GABRB1, GABRB3 | CYP3A4 254/4885IDO1 2081/4885ADRA2A 221/4885 |
| US-20050227992-A1 | Protein kinase inhibitors | CDK2, MAP3K1, MAP3K2 | CYP3A4 2682/4885IDO1 2765/4885ADRA2A 3907/4885 |
| US-20230062712-A1 | ANTI-ASGR1 ANTIBODY CONJUGATES AND USES THEREOF | ASGR1, HAVCR2, FCGR2A | CYP3A4 4082/4885IDO1 774/4885ADRA2A 1391/4885 |
| US-20050277658-A1 | Protein kinase inhibitors | CDK2, MAP3K1, MAP3K2 | CYP3A4 2682/4885IDO1 2765/4885ADRA2A 3907/4885 |
| US-20050239794-A1 | Protein kinase inhibitors | CDK2, MAP3K1, MAP3K2 | CYP3A4 2682/4885IDO1 2765/4885ADRA2A 3907/4885 |
| US-20050239793-A1 | Protein kinase inhibitors | CDK2, MAP3K1, MAP3K2 | CYP3A4 2682/4885IDO1 2765/4885ADRA2A 3907/4885 |
| US-12364768-B2 | Nectin-4 antibody conjugates and uses thereof | NECTIN4, SIGLEC7, CD2 | CYP3A4 3809/4885IDO1 3265/4885ADRA2A 2783/4885 |
| US-11541126-B1 | Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereof | ASGR1, TLR8, HAVCR2 | CYP3A4 4056/4885IDO1 602/4885ADRA2A 817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.